Evidence map›Paper›PMID 39477394›Full record

ArticleIn vivo (Athens, Greece)

Is There a Correlation Between Platelet Count, Mesenteric Lymph Node Involvement, and Hematogenous Metastases in Advanced Stage Ovarian Cancer?

Nicolae Bacalbasa, Sorin Petrea, Bogdan Gaspar, Lucian Pop, Valentin Varlas, Adrian Hasegan, Gabriel Gorecki, Cristina Martac, Marilena Stoian, Anca Zgura and 2 more

Abstract read
In one paragraph

Article in In vivo (Athens, Greece). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Nicolae Bacalbasa *Department of Visceral Surgery, Center of Excellence in Translational Medicine "Fundeni" Clinical Institute, Bucharest, Romania.
Sorin Petrea *Department of Surgery, "Carol Davila" University of Medicine and Pharmacy, Bucharest, Romania.
Bogdan Gaspar *Department of Surgery, "Carol Davila" University of Medicine and Pharmacy, Bucharest, Romania.
Lucian PopDepartment of Obstetrics and Gynecology, "Carol Davila" University of Medicine and Pharmacy, Bucharest, Romania.
Valentin VarlasDepartment of Obstetrics and Gynecology, "Carol Davila" University of Medicine and Pharmacy, Bucharest, Romania.
Adrian HaseganDepartment of Urology, Sibiu Emergency Hospital, Faculty of Medicine, University of Sibiu, Sibiu, Romania.
Gabriel GoreckiDepartment of Anesthesia and Intensive Care, CF 2 Clinical Hospital, Bucharest, Romania.
Cristina MartacDepartment of Anesthesiology, Fundeni Clinical Hospital, Bucharest, Romania.
Marilena Stoian *Department of Internal Medicine, "Carol Davila" University of Medicine and Pharmacy, Bucharest, Romania.
Anca ZguraDepartment of Medical Oncology, Oncological Institute Prof. Dr. Al. Trestioreanu, Bucharest, Romania.
Alexandru Ciulcu *Department of Obstetrics and Gynecology, "Ion Cantacuzino" Clinical Hospital, Bucharest, Romania; aciulcu2000@yahoo.com.
Irina BalescuPh.D. Student at "Carol Davila" University of Medicine and Pharmacy, Bucharest, Romania.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND/

aimOvarian cancer remains a major cause of death in women worldwide, mainly due to late diagnosis and the lack of a reliable screening test for early detection of the disease. In this context, attention has been focused on the identification of other prognostic factors that might allow a better identification of cases with worse long-term outcome. PATIENTS AND

methodsData of patients who underwent cytoreductive surgery between 2014-2019 were retrospectively reviewed and 57 patients were considered eligible for this study. These cases were further classified according to preoperative platelet count, with a cut-off value of 335,000/μl as a positive predictive value for long-term survival.

resultsAccording to this value, there were 27 cases with a preoperative platelet count lower than 335,000/μl and 30 cases with a preoperative platelet count higher than 335,000/μl. Cases in the second group had a significantly higher peritoneal carcinomatosis index (p=0.002), a higher proportion of digestive serosa involvement (p<0.001), and a higher proportion of mesenteric lymph node involvement and hematogenous metastases (p=0.005 and p=0.001, respectively). When analyzing long-term outcomes, all these factors had a significant impact on overall survival.

conclusionPreoperative thrombocytosis appears to be positively associated with gastrointestinal serosa involvement, mesenteric lymph node invasion, and the presence of hematogenous metastases, thus significantly influencing the long-term outcome of patients with advanced ovarian cancer.

Indexed as

Lymphatic MetastasisLymph NodesNeoplasm StagingOvarian NeoplasmsAdultAgedCytoreduction Surgical ProceduresFemaleHumansMiddle AgedPlatelet CountPrognosisRetrospective Studiesdigestive serosahematogenous metastasesmesenteric involvementPlateletssurvival

Identifiers

PMID39477394
PMCPMC11535961

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.